/C O R R E C T I O N - LifeStance Health/
Key Highlights
- ➤Esketamine reduced depression severity meaningfully for 74% of 258 patients after 12 weeks
- ➤Esketamine reduced near-daily suicidal ideation from 13% to 2%
- ➤TMS reduced depression severity meaningfully for 61% of 355 patients after 30 sessions
- ➤TMS reduced near-daily suicidal ideation from 13% to 6%
- ➤LifeStance is expanding access to esketamine and TMS specialty services nationwide
Expert Statements
Stephanie Eken, Chief Medical Officer, LifeStance Health
“For patients with treatment-resistant depression, not finding relief from previous treatments does not mean they are out of options.”
Stephanie Eken, Chief Medical Officer, LifeStance Health
“The improvements we're seeing at LifeStance with esketamine and TMS offer new hope for patients who have continued to struggle, including those experiencing the most severe symptoms and suicidal ideation.”
Stephanie Eken, Chief Medical Officer, LifeStance Health
“Too many patients are still waiting for relief when there are effective, evidence-based treatment options that may help.”
Stephanie Eken, Chief Medical Officer, LifeStance Health
“We're committed to expanding access to these specialty services so more patients have the opportunity to receive the most effective treatments tailored to their individual clinical needs.”
In the news release, LifeStance Patients With Treatment-Resistant Depression See Clinically Meaningful Improvement in Symptoms After Esketamine or TMS Treatment, New Data Shows, issued 29-Oct-2026 by LifeStance Health over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end: LifeStance Patients With Treatment-Resistant Depression See Clinically Meaningful Improvement in Symptoms After Esketamine or TMS Treatment, New Data Shows
LifeStance Expands Specialty Services, Increasing Access to Esketamine (Spravato) and Transcranial Magnetic Stimulation (TMS) Across the U.S.
Get started
Create a free account to read the full story.